Document Detail


Anaplastic astrocytoma.
MedLine Citation:
PMID:  23543397     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Abstract/OtherAbstract:
Standard treatment of anaplastic astrocytoma (AA) in good performance patients consists of maximal safe surgical resection followed by focal, fractionated, external beam radiotherapy (RT) alone or in combination with concurrent and adjuvant temozolomide (TMZ). Since prospective data regarding the use of chemoradiotherapy for AA is lacking, the practice is based on the extrapolation of results from a randomized study in glioblastoma (GB). Whether the data from the GB study can and should be extrapolated is controversial, although a large multicenter, randomized, phase III study is underway to define optimal initial AA treatment. Patients should be tapered off corticosteroids completely or to the lowest dose necessary to treat neurologic dysfunction. Anti-epileptic drugs (AED) are not indicated unless there is a history of seizure; levetiracetam is the preferred AED in malignant glioma (MG). Unless there is evidence of intracranial hemorrhage, venous thromboembolism (VTE) should be treated with low-molecular-weight heparin (LMWH) therapy. At recurrence, patients with good performance status are usually treated with cytotoxic chemotherapy following, or in lieu of, repeat surgery. TMZ is the preferred chemotherapeutic agent in patients without prior exposure; lomustine is recommended for tumors resistant to TMZ. In patients with neurologic dysfunction secondary to tumor edema and mass effect who are not amenable to surgery, the use of bevacizumab is associated with improved neurologic function and better quality of life. Given the limited treatment options at tumor recurrence, consideration for enrollment on a clinical trial is encouraged.
Authors:
Sean A Grimm; Thomas J Pfiffner
Related Documents :
16709037 - New trends in the medical management of glioblastoma multiforme: the role of temozolomi...
8820767 - High-grade astrocytomas: resource use, clinical outcomes, and cost of care.
23102757 - Long-term control of refractory hemorrhagic radiation proctitis with ozone therapy.
9865917 - Gamma-ray mutagen sensitivity and survival in patients with glioma.
6390537 - Current trend in the treatment of hodgkin's disease.
18621047 - Tips for budd-chiari syndrome: long-term results and prognostics factors in 124 patients.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current treatment options in neurology     Volume:  15     ISSN:  1092-8480     ISO Abbreviation:  Curr Treat Options Neurol     Publication Date:  2013 Jun 
Date Detail:
Created Date:  2013-05-13     Completed Date:  2013-05-14     Revised Date:  2013-07-25    
Medline Journal Info:
Nlm Unique ID:  9815940     Medline TA:  Curr Treat Options Neurol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  302-15     Citation Subset:  -    
Affiliation:
Department of Neurology, University of Minnesota School of Medicine, 420 Delaware Street SE, MMC 295, Minneapolis, MN, 55455, USA, sgrimm@umn.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Enabling interspecies epigenomic comparison with CEpBrowser.
Next Document:  Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes...